Forty-three patients with miliary tuberculosis were evaluated for diagnostic usefulness of enzyme-linked immunospot (ELISPOT) assay. Among noninvasive rapid tests available within 3-5 days, ELISPOT had the highest sensitivity (93%), compared with acid-fast bacilli stain (sputum, 32% and bronchoalveolar lavage, 7%), Mycobacterium tuberculosis polymerase chain reaction (sputum, 53% and bronchoalveolar lavage, 36%), and tuberculin skin test (22%). In comparison with 44 patients with lymph node tuberculosis, the sensitivity of the ELISPOT assay in patients with miliary tuberculosis (93%) was as high as in those with lymph node tuberculosis (95%, P = .63), whereas the sensitivity of the tuberculin skin test was substantially lower in patients with miliary tuberculosis (22%) than in those with lymph node tuberculosis (73%, P < .001).
promising results as a diagnostic tool for latent or active tuberculosis [1] . However, little is known about the usefulness of this assay for diagnosing miliary tuberculosis. We therefore prospectively evaluated its usefulness compared with traditional tests, and also compared the diagnostic performances of the ELISPOT assay and the tuberculin skin test (TST) in patients with miliary versus lymph node tuberculosis.
METHODS
All adult patients with suspected miliary tuberculosis or lymph node tuberculosis admitted to the Asan Medical Center, a 2700-bed tertiary hospital in Seoul, South Korea, between April 2008 and March 2012 were prospectively enrolled. We only included the first test results of ELISPOT assay and TST at the time of diagnosis for miliary and lymph node tuberculosis. The ELISPOT assay (T-SPOT.TB; Oxford Immunotec, Abingdon, UK) was performed as previously described [1] [2] [3] . The TST was performed by the Mantoux technique, injecting a 2-tuberculin unit dose of purified protein derivative RT23 (Statens Serum Institut, Copenhagen, Denmark) [1] . The positive criterion for the TST was a 10 mm or greater induration 48 hours after injection [1] [2] [3] [4] . TST has not been used in our hospital for routine diagnostic test for patients with suspected tuberculosis since January 2011, on the basis of our previous reports [1-3, 5, 6] . Mycobacterium tuberculosis polymerase chain reaction (PCR) (AccuProbe Mycobacterium complex culture identification kit; Gen-Probe, San Diego, California), microbiologic and pathological specimens were processed using standard techniques and procedures, as described elsewhere [1] [2] [3] [5] [6] [7] .
The diagnosis of miliary tuberculosis was made according to previously proposed criteria [8] : clinical presentation consistent with tuberculosis responding to antituberculous treatment, with a typical miliary pattern on chest radiograph and/ or bilateral, diffuse reticulonodular lung lesions on a background of miliary shadows seen on chest radiographs or highresolution computed tomography scans, plus microbiological evidence of tuberculosis such as positivity for M. tuberculosis by culture or by M. tuberculosis PCR (confirmed tuberculosis) and/or histopathological evidence of tuberculosis such as caseating granuloma in biopsy specimens ( probable tuberculosis). The clinical categories of patients with lymph node tuberculosis have been described previously [1, 3] . Patients were classified as having possible tuberculosis if they did not fulfill any of the above criteria but miliary or lymph node tuberculosis could not be excluded. Patients with possible tuberculosis were excluded from the final analysis.
RESULTS

Patient Characteristics
A total of 44 subjects with suspected miliary tuberculosis and 46 with suspected lymph node tuberculosis were prospectively enrolled. Of the patients with suspected miliary tuberculosis, 43 (98%) were subsequently classified as having tuberculosis, including 37 (84%) with confirmed tuberculosis, and 6 (14%) with probable tuberculosis. Of the 46 patients with suspected lymph node tuberculosis, 44 (96%) were classified as having tuberculosis, including 34 (74%) with confirmed tuberculosis and 10 (22%) with probable tuberculosis. The remaining 1 patient (2%) with possible miliary tuberculosis and 2 patients (4%) with possible lymph node tuberculosis were excluded from the final analysis. All patients underwent ELISPOT assays using their blood samples. Twenty-seven (63%) patients with miliary tuberculosis and 26 (59%) with lymph node tuberculosis received TST because our hospital policy for use of TST as a routine diagnostic test was changed. However, there were no significant differences in baseline clinical characteristics between patients who did and did not receive TST (data not shown). Of 53 patients who underwent both ELISPOT assay and TST, 49 (93%) received blood sampling for ELISPOT assay prior to TST. The remaining 4 (7%) received blood sampling after TST. The baseline characteristics of the patients with miliary or lymph node tuberculosis are shown in Supplementary Table 1 .
Results of the Diagnostic Tests for Miliary Tuberculosis
The sensitivities of the various diagnostic tests in patients with miliary tuberculosis are shown in Table 1 . The sensitivities of sputum and bronchoalveolar lavage (BAL) M. tuberculosis culture were 68% (95% confidence interval [CI], 53%-80%) and 57% (95% CI, 33%-79%), respectively. Among noninvasive rapid diagnostic tests whose results were available within 3-5 days, the ELISPOT assay had the highest sensitivity (93% [95% CI, 81%-98%]), compared with the acid-fast bacilli (AFB) stain (sputum, 32% [95% CI, 20%-47%] and BAL, 7% [95% CI, 1%-31%]), M. tuberculosis PCR (sputum, 53% [95% CI, 31%-74%] and BAL, 36% [95% CI, 16%-61%]), and TST (22% [95% CI, 11%-41%]). Histopathologic examination of transbronchial lung biopsy specimens was found to be the most sensitive diagnostic test for miliary tuberculosis (sensitivity 100% [95% CI, 57%-100%]), although these procedures were performed in limited numbers of patients (n = 5).
The sensitivities of the TST and ELISPOT assay in patients with miliary tuberculosis and lymph node tuberculosis, respectively, are shown in Supplementary Table 2 . The TST had lower sensitivity in patients with miliary tuberculosis (22%) than in those with lymph node tuberculosis (73%, P < .001). In contrast, the ELISPOT assay was as sensitive in patients with miliary tuberculosis (93%) as in those with lymph node tuberculosis (95%, P > .99).
Responses to ESAT-6 and CFP-10, and Induration Size of the Tuberculin Skin Test in Patients With Miliary Tuberculosis
We compared responses to ESAT-6 and CFP-10, and induration sizes in patients with miliary tuberculosis vs lymph node tuberculosis (Supplementary Figure 1) . The indurations in patients with miliary tuberculosis were smaller than in those with lymph node tuberculosis, whereas the responses to ESAT-6 and CFP-10 were stronger in patients with miliary tuberculosis than in those with lymph node tuberculosis.
DISCUSSION
Rapid diagnosis and treatment are important prognostic factors for patients with miliary tuberculosis [8, 9] . As shown in our study and in previous studies [10] , histopathological examination of biopsy specimens obtained by invasive procedures can provide rapid and sensitive results (65%-100%). However, obtaining a tissue biopsy sample is not without risk in a patient with suspected miliary tuberculosis. The conventional rapid, noninvasive diagnostic tests have low sensitivity in the case of miliary tuberculosis. The sensitivities of the sputum AFB stain and sputum M. tuberculosis PCR in patients with miliary tuberculosis are reported as approximately 61% and 79%, respectively [11, 12] . It was supposed that the sensitivity of sputum AFB stain might be increased by using BAL, but it has been shown that the sensitivities of the sputum AFB stain and M. tuberculosis PCR from BAL specimens in patients with miliary tuberculosis are not high enough to guide empirical therapy [10, 13] . In this problematic clinical situation, our study demonstrates that, of the noninvasive rapid diagnostic tests available within 3-5 days, ELISPOT assays have greater sensitivity (93%) than the AFB stain (sputum, 32%; BAL, 7%), M. tuberculosis PCR (sputum, 53%; BAL, 36%), or the TST (22%). Therefore, the ELISPOT assay may be a useful adjunctive diagnostic tool for miliary tuberculosis.
It has been noted that the sensitivity of the TST is as low as approximately 32% in patients with miliary tuberculosis [8] . Therefore, our finding that the sensitivity of the TST in patients with miliary tuberculosis was 22% is in line with the previous studies. The mechanisms of anergy to TST in patients with miliary tuberculosis have not been clearly defined. Some experts have noted that "desensitization" to mycobacterial antigens due to exposure to large amount of tuberculosis bacilli in the bloodstream can lead to anergy to the TST [14] . Another possible explanation of the low sensitivity of the TST is that patients with miliary tuberculosis are frequently immunocompromised, and immunosuppression itself may contribute to the low sensitivity of the TST. This idea is supported by our previous finding that the TST is less sensitive in immunocompromised patients than in immunocompetent ones [3] . In contrast to the TST in patients with miliary tuberculosis, these patients gave higher responses in the ELISPOT assay than patients with lymph node tuberculosis (Supplementary Figure 1) . Although the reason of this difference is not known, we can infer from our findings that reactivity to the TST is more affected by immunosuppression in the host than by the antigenic load, whereas sensitivity to the ELISPOT assay is strongly affected by the antigenic load with only a slight effect of immunosuppressed status. This difference is in line with previous studies. First, it has been shown that the reduced antigenic load following antituberculous treatment in patients with tuberculosis or latent tuberculosis results in decreased responsiveness to RD1 peptides [15] . Second, we showed previously that immunosuppression itself did not affect quantitative responses to RD1 peptides ( Figure 2C in [2] ), although the sensitivity of the ELISPOT assay was also slightly lower in immunocompromised patients than in nonimmunocompromised patients.
In conclusion, the ELISPOT assay may be a helpful adjunct test for miliary tuberculosis. We could not investigate diagnostic performance, including specificity, positive predictive value, and negative predictive value, as no control patients with diseases imitating miliary lung nodules were included in our study. Thus, additional studies with the involvement of controls in various regions are needed to define the diagnostic flow of patients with miliary lung nodules.
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